.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia: Where are we in 2023?

EP. 1: Dr Coombs on BTK Inhibitors and CAR T-Cell Therapy in CLL

July 14th 2023

Callie Coombs, MD, discusses treatment updates in patients with chronic lymphocytic leukemia.

EP. 2: Dr Danilov on Therapeutic Options After BTK Inhibitors in MCL

July 14th 2023

Alexey Danilov, MD, PhD, discusses treatment developments for patients with mantle cell lymphoma who have progressed on BTK inhibitors.

EP. 3: Data With Novel Agents Prompt Treatment Sequencing Discussions in MCL and CLL

August 3rd 2023

Catherine C. Coombs, MD, and Alexey Danilov, MD, PhD, moderate a discussion on the role and sequencing of BTK inhibitors, venetoclax-based regimens, and CAR T-cell therapy in mantle cell lymphoma and chronic lymphocytic leukemia.